Nicotinamide Supplements Boost Breast Milk B3 But Don't Improve Infant Growth
A Tanzania RCT finds maternal nicotinamide supplementation raises breast milk B3 levels dramatically, yet shows no link to infant growth or cognitive outcomes.
Summary
A randomized controlled trial in rural Tanzania tested whether giving lactating mothers 250 mg of nicotinamide daily would improve infant outcomes through breast milk. The supplementation dramatically increased vitamin B3 concentrations in breast milk — by nearly 300% — pushing most supplemented mothers well above normal reference ranges. Without supplementation, a growing proportion of mothers had low B3 levels by month five of lactation, suggesting dietary inadequacy in this maize-dependent population. Despite the significant effect on breast milk composition, researchers found no association between breast milk B3 levels and infant weight, height, head circumference, or cognitive development scores at 18 months. This raises important questions about whether boosting a single nutrient is sufficient to influence infant development in complex nutritional environments.
Detailed Summary
Vitamin B3 deficiency is a real risk in populations that rely heavily on maize without traditional preparation methods that improve niacin bioavailability. In sub-Saharan Africa, where diets are often maize-centered and protein-poor, lactating mothers may fail to deliver adequate B3 through breast milk — potentially affecting infant growth and brain development.
This secondary analysis examined data from the ELICIT trial, an RCT conducted in Haydom, Tanzania, involving 1,173 mother-infant dyads. Lactating mothers were randomized to receive either 250 mg/day of nicotinamide or placebo from within two weeks postpartum through six months. Breast milk samples were collected at months one and five and compared against international reference ranges from the MILQ study. Child outcomes including weight, height, head circumference, and cognitive development (via the Malawi Developmental Assessment Tool) were tracked through 18 months.
The results revealed a stark divergence in breast milk B3 levels. Without supplementation, the proportion of mothers with below-reference B3 concentrations rose from 2.9% at month one to 28.8% by month five — a troubling trend suggesting progressive nutritional depletion during lactation. Supplementation reversed this, but overcorrected dramatically: over 70% of supplemented mothers exceeded the upper reference limit at month one, and median B3 concentration was nearly four times higher than placebo.
Despite these pronounced biochemical differences, no associations were found between breast milk B3 concentrations and any infant growth or developmental outcome at 18 months. This null finding persisted across all measured anthropometric and cognitive endpoints.
These results highlight a recurring challenge in nutrition intervention research: improving a single nutrient biomarker does not automatically translate into measurable health benefits, particularly in settings with multifactorial nutritional deficiencies. The findings suggest that B3 alone may not be a limiting factor for infant development in this population, or that outcomes require longer follow-up or broader nutritional co-interventions to manifest.
Key Findings
- Without supplementation, 28.8% of mothers had below-reference breast milk B3 by month five of lactation.
- Nicotinamide supplementation raised breast milk B3 by ~291% at month one and ~281% at month five.
- Over 72% of supplemented mothers exceeded the upper B3 reference limit at month one.
- No association found between breast milk B3 levels and infant weight, height, or head circumference through 18 months.
- No link detected between breast milk B3 and cognitive development scores at 18 months.
Methodology
This was a secondary analysis of the ELICIT RCT (NCT03268902), a randomized, placebo-controlled trial of 1,173 mother-infant dyads in rural Tanzania. Mothers received 250 mg/day nicotinamide or placebo from within two weeks postpartum to six months. Breast milk B3 vitamers were measured at months one and five; child growth and cognitive outcomes were assessed through 18 months.
Study Limitations
This summary is based on the abstract only, as the full text was not available, limiting assessment of statistical methods, confounders controlled, and secondary outcome analyses. The null findings on infant outcomes may reflect insufficient follow-up duration, a population with multiple concurrent nutritional deficiencies that attenuate single-nutrient effects, or underpowered subgroup analyses. Generalizability beyond rural Tanzanian populations with similar maize-heavy diets is uncertain.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.